Exosome therapy: what is actually studied, what is sold, and how to tell them apart

What it is

Exosomes are extracellular vesicles — membrane-bound packets 30–150 nanometres across — that cells release to signal to each other. They carry proteins, lipids and RNA, including microRNAs that can change the behaviour of the receiving cell. The therapeutic interest centres on exosomes released by mesenchymal stem cells (MSCs), because much of what MSCs do in a wound appears to be done by what they secrete rather than by the cells themselves.

That is the attraction: a cell-free product with a stem cell's signalling, no risk of the cells dividing where they should not, easier to store and to dose. The difficulty is that "exosome" describes a size range, not a defined product. Two vials from two laboratories can share the name and have almost nothing else in common — different source cells, different culture conditions, different cargo, different concentration, and in unregulated products, sometimes no vesicles at all.

What the research says

In short: the mechanistic and animal work is genuinely interesting, the human evidence is thin, and the only use with any controlled data is topical application to skin after a resurfacing procedure.

Protocols that are studied

There is no standard protocol, because there is no standard product. What the published human studies and trial registrations describe:

• Topical, skin. A lyophilised or liquid preparation applied immediately after microneedling or fractional laser, then for several days at home. Typically 2–4 procedures spaced a month apart.
• Intra-articular, joints. A single injection or a short series into the knee under ultrasound, in registered trials only, with doses expressed as particle count (billions of vesicles) rather than milligrams.
• Intravenous, systemic. Used in phase 1 safety trials for inflammatory and lung conditions. Outside a trial, intravenous exosomes are where the serious adverse events have occurred.
• Scalp injection. Small volumes across thinning areas, in uncontrolled series.

Note what is missing: an agreed dose, an agreed potency assay, and any data on repeat courses.

Who it suits — and who should avoid it

The honest answer is that outside a registered trial, it suits very few people. The best case is someone already having a skin resurfacing procedure with a physician who uses a characterised, lab-released topical product and can show the certificate of analysis. Everything injected or infused belongs in a trial or a properly licensed hospital setting.

Avoid, or treat as a hard physician conversation

• Any history of cancer — MSC-derived vesicles carry growth-promoting signals; the precaution is universal in the trial exclusion criteria.
• Pregnancy and breastfeeding, autoimmune disease on immunosuppression, active infection.
• Anyone offered intravenous exosomes outside a trial. In 2019 a cluster of patients in the United States developed sepsis-like reactions after unapproved exosome infusions; the regulator's warning that followed is still in force.
• Anyone who cannot be shown the product's source, sterility testing and particle characterisation. If the paperwork does not exist, the product is unknown.

Where it fits in a personal protocol

It mostly does not — yet. Longevity Bros does not provide, arrange or recommend exosome products. What a protocol does is say so plainly when a client arrives wanting them, lay out the evidence table above, and point to the layers of the plan with actual data for the same goal: for skin, GHK-Cu and red light; for joints and soft tissue, the Wolverine combination and PRP, which at least has randomised trials.

If a client still wants to pursue exosomes, the route is on request, through a physician: the physician copy of the protocol notes the question, and the client's own doctor decides whether a licensed setting or a registered trial exists for it. A coach can help frame the questions; a coach cannot and does not source anything.

The hype vs the evidence

• "Exosome IV for anti-ageing." No human trial, a documented cluster of serious harm, and a product with no agreed standard. The clearest "no" on this site.
• "Billions of exosomes per vial." Particle counts include cell debris and lipoproteins. Without a potency assay the number means nothing.
• "Approved by the regulator." No exosome product is approved for any use in the US or EU at the time of writing. Laboratory registration is not product approval.
• What is genuinely promising: topical use after resurfacing, with a characterised product from a physician who can show the paperwork — and the registered joint trials, when they report.